The optimisation of the azanaphthyridine series of Spleen Tyrosine Kinase inhibitors is described. The medicinal chemistry strategy was focused on optimising the human whole blood activity whilst achieving a sufficient margin over hERG activity. A good pharmacokinetic profile was achieved by modification of the pKa. Morpholine compound 32 is a potent SYK inhibitor showing moderate selectivity, good oral bioavailability and good efficacy in the rat Arthus model but demonstrated a genotoxic potential in the Ames assay.
Keywords: Azanaphthyridine; Lead optimisation; Medicinal chemistry; Orally bioavailable; Potent; SYK; Selective; Spleen Tyrosine Kinase.
Copyright © 2016 Elsevier Ltd. All rights reserved.